XNYSINSP
Market cap6.41bUSD
Jan 08, Last price
213.89USD
1D
-0.71%
1Q
4.11%
IPO
774.09%
Name
Inspire Medical Systems Inc
Chart & Performance
P/E
—
P/S
10.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.98%
Rev. gr., 5y
65.32%
Revenues
625m
+53.19%
Net income
-21m
L-52.87%
CFO
25m
+113.10%
Dividend
Jan 09, 20089 USD/sh
Earnings
Feb 04, 2025
Profile
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 624,799 53.19% | 407,856 74.75% | |||||||
Cost of revenue | 665,070 | 455,448 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (40,271) | (47,592) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,247 | 613 | |||||||
Tax Rate | |||||||||
NOPAT | (41,518) | (48,205) | |||||||
Net income | (21,153) -52.87% | (44,881) 6.75% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 13,950 | 259,577 | |||||||
BB yield | -0.23% | -3.67% | |||||||
| Debt | |||||||||
Debt current | 1,336 | ||||||||
Long-term debt | 74,538 | 15,072 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (23,500) | 146 | |||||||
Net debt | (394,980) | (445,505) | |||||||
| Cash flow | |||||||||
Cash from operating activities | 24,653 | 11,569 | |||||||
CAPEX | (23,629) | (9,096) | |||||||
Cash from investing activities | (294,822) | (19,596) | |||||||
Cash from financing activities | 13,950 | 235,077 | |||||||
FCF | (116,530) | (52,747) | |||||||
| Balance | |||||||||
Cash | 460,375 | 451,413 | |||||||
Long term investments | 9,143 | 10,500 | |||||||
Excess cash | 438,278 | 441,520 | |||||||
Stockholders' equity | (344,593) | (324,327) | |||||||
Invested Capital | 943,299 | 829,353 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 29,302 | 28,072 | |||||||
Price | 203.43 -19.24% | 251.88 9.48% | |||||||
Market cap | 5,960,937 -15.70% | 7,070,712 12.73% | |||||||
EV | 5,565,957 | 6,625,207 | |||||||
EBITDA | (37,425) | (45,734) | |||||||
EV/EBITDA | |||||||||
Interest | 1,677 | ||||||||
Interest/NOPBT | |||||||||